Inolitazone
Inolitazone a novel high-affinity PPARγ agonist that is dependent upon PPARγ for its biological activity with IC50 of 0.8 nM for growth inhibition.
Product Specifications
CAS Number
223132-37-4
Product Name Alternative
Efatutazone; CS-7017; RS5444
UNSPSC
12352005
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/inolitazone.html
Solubility
10 mM in DMSO
Smiles
O=C(N1)SC(CC2=CC=C(OCC3=NC4=CC=C(OC5=CC(C)=C(N)C(C)=C5)C=C4N3C)C=C2)C1=O
Molecular Formula
C27H26N4O4S
Molecular Weight
502.58
References & Citations
[1]Copland JA, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13;25 (16) :2304-17.|[2]Marlow LA, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009 Feb 15;69 (4) :1536-44.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PPARγ
Citation 01
Exp Cell Res. 2017 Dec 15;361 (2) :246-256. |Front Microbiol. 2019 Jan 8:9:3257.|bioRxiv. 2025 Oct 22.|Cancer Med. 2018 May;7 (5) :1955-1966. |Int J Oncol. 2018 Jun;52 (6) :1991-2000.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
